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ABSTRACT Transforming growth factor-beta (TGF-β) and adrenomedullin are multifunctional
regulatory proteins which are expressed in developing embryonic and adult tissues. Because of
their co-localization, TGF-β1 and adrenomedullin may be able to coordinately act to influence
development and differentiation. In order to learn more about the biology of adrenomedullin in the
absence of the effects of TGF-β1 in vivo, we examined adrenomedullin in the TGF-β1 null mouse. A
generally lower amount of adrenomedullin was detected by immunohistochemical staining
analysis in multiple tissues from embryonic TGF-β1 null mice compared to wildtype animals,
including the heart, lung, brain, liver, and kidney, among others. In contrast, immunohistochemical
staining for adrenomedullin was more intense in tissues of the postnatal TGF-β1 null mouse
compared to the wildtype mouse. These observations were confirmed by quantitative real time RT-
PCR for adrenomedullin in both embryos and postnatal animals, as well as in cultured mouse
embryo fibroblasts from TGF-β1 null and wildtype mice. In addition, when cultured mouse embryo
fibroblasts were treated with a neutralizing monoclonal antibody against TGF-β1, the levels of
adrenomedullin expression were statistically reduced compared to untreated cells. Our data show
that expression of adrenomedullin is reduced in tissues of the developing embryonic TGF-β1 null
mouse compared to the wildtype mouse, but increases during postnatal development in TGF-β1
null mice. The elevated expression of adrenomedullin which occurs postnatally in the TGF-β1 null
mouse may be a cause or a consequence of the multifocal wasting syndrome which is characteristic
of postnatal TGF-β1 null mice.
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Several different polypeptide growth factors have been identified in
normal developing mice, including adrenomedullin (AM) and trans-
forming growth factor-beta (TGF-β). AM is a multifunctional regula-
tory molecule with several biological activities, and has been shown
to stimulate or inhibit the proliferation of different cells (reviewed in
López and Martínez, 2002). AM has been shown to be secreted by
a variety of normal and malignant cells in culture (Martínez et al.,
1995; Miller et al., 1996) and is expressed in a variety of embryonic
and adult tissues (Montuenga et al., 1997, 1998). Deletion of the
AM gene results in embryonic lethality with hydrops fetalis, and
cardiovascular abnormalities. TGF-β is also a multifunctional regu-
latory polypeptide that is the prototypical member of a large family
of cytokines that controls many aspects of cellular function (re-
viewed in Massagué et al., 2000). TGF-β1 is a potent
immunoregulatory molecule that can both suppress and enhance
cell functions in vitro and in vivo. Targeted disruption of gene
expression through homologous recombination in mouse embryonic
stem cells for TGF-β1 revealed a principal function in the mainte-
nance of immunological homeostasis. Two to three weeks after birth,
the TGF-β1 null mouse develops a wasting syndrome characterized
by weight loss and multifocal infiltration of inflammatory cells in many
organs such as the lungs, heart, and salivary glands, and progresses
until the vital functions of the heart and lung are compromised (Schull
et al., 1992; Kulkarni et al., 1993).
We have shown that expression of TGF-β1 and AM is regulated
in a spatial and temporal manner such that overlapping patterns
of TGF-β1 and AM expression occur in many tissues at the same
stage of development and in the same cellular location in rodent
embryogenesis (Montuenga et al., 1998). The spatio-temporal
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patterns of expression of TGF-β1 and AM in cardiovascular,
neural, and skeletal-forming tissues as well as in the main
embryonic internal organs show striking similarities. Moreover,
the lung, kidney, and intestine, in which epithelial-mesenchymal
interactions occur, show similar patterns of TGF-β1 and AM
expression. A more extensive knowledge of the biology of TGF-
β could provide clues to the functions of AM. Here, we have
examined AM during development of TGF-β1 null mice and
compared it with wildtype (WT) littermates.
The immunohistochemical staining pattern of AM in TGF-β1 null
mice was established and compared with WT littermates in several
embryonic tissues ranging in age from E11 to E19. Figure 1A shows
a low power image of the heart and lung of an E16 WT mouse in which
both the ventricle and atrium as well as lung parenchyma show
positive immunostaining for AM. In contrast, Fig. 1B shows weak
immunostaining for AM in the heart and lung parenchyma of an E16
TGF-β1 null mouse. Immunohistochemical staining for AM was
completely blocked when the AM antibody was preincubated with its
peptide immunogen (Fig. 1A inset). Figure 1C shows a higher
magnification of the lung parenchyma of an E16 WT mouse
immunostained for AM, and compares it with the lung of a TGF-β1
null mouse of the same age (Fig. 1D). The intensity of immunostaining
for AM in epithelial cells of the forming airways and in several isolated
cells in the differentiating mesenchyme of the WT lung is consider-
ably stronger than in the lung of the TGF-β1 null mouse. Figure 1E
shows that while there is intense staining for AM in the cartilage plate
of a developing rib of an E16 WT embryo, the intensity of staining for
AM is markedly reduced in the chondrocytes in a TGF-β1 null mouse
of the same age (Fig. 1F). The immunostaining pattern of AM in the
dorsal root ganglia of an E16 WT mouse (Fig. 1G) shows moderately
intense staining of neurons while these same neurons show only
weak immunostaining in the TGF-β1 null mouse embryo (Fig. 1H).
Table 1 shows a comparison of immunohistochemical staining
intensity for AM in several tissues from E16 and E20 TGF-β1 null and
WT mice. The intensity of immunohistochemical staining for AM was
strong in heart and dorsal root ganglia and moderate in lung, liver,
kidney, chondrocytes, and brain of embryonic WT mice of both ages
compared to TGF-β1 null mice. Our demonstration of reduced levels
of AM protein in several tissues of the embryonic TGF-β1 null mouse
compared to its wildtype littermates shows that AM expression is
affected by deletion of the TGF-β1 gene. Whether reduced expres-
sion of AM in the embryonic TGF-β1 null mouse is a direct effect of
deletion of the two TGF-β1 alleles or a secondary effect that follows
from intermediate changes is not known.
To investigate the localization of AM protein in postnatal
development of TGF-β1 null mice, the immunohistochemical
staining pattern of AM was examined in several organs of postna-
Fig. 1. Expression of AM protein in
organs from developing TGF-β1
null and wildtype mouse embryos
and postnatal mice. (A-H) Immu-
nohistochemical staining of E16 em-
bryos. (I-P) Immunohistochemical
staining of P-19 mice. (A,C,E,G)
Wildtype (WT) embryos. (B,D,F,H)
TGF-β1 null (KO) embryos. (I,K,M,O)
Postnatal WT mice. (J,L,N,P) Post-
natal TGF-β1 null mice. A,B, Heart
and lung. C,D, Lung. E,F, Cartilage
plate. G,H, Dorsal root ganglia. I,J,
Liver. K,L, Brain. M,N, Heart. O,P,
Cartilage and bone. Magnification:
bars: A, B and A inset 250 µm; E, F,
O, and P 100 µm; C, D, M, and N 50
µm; G, H-L 25 µm.
TABLE 1
IMMUNOHISTOCHEMICAL STAINING INTENSITY OF AM PROTEIN
DURING MOUSE EMBRYOGENESIS AND POSTNATAL DEVELOPMENT
IN TGF-β1 NULL AND WILDTYPE MICE
E16 E20 P-7 P-17 P-19
WT KO WT KO WT KO WT KO WT KO
Heart 3 1 3 1 3 1 2 2 1 2
Lung 2 1 2 1 2 1 1 2 1 2
Liver 2 1 2 1 2 1 1 2 1 2
Kidney 2 1 2 1 2 1 1 2 1 2
DR Ganglia 3 1 3 1 3 1 2 2 1 2
Chondrocytes 2 1 2 1 2 1 1 2 1 2
Brain 2 1 2 1 2 1 1 3 1 3
Staining intensity is ranked 0, no; 1, weak; 2, moderate; 3, intense. KO, TGF-β1 null; WT, wildtype.
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tal TGF-β1 null mice and compared with wildtype littermates in
several tissues ranging in age from P-7 to P-19. While Fig. 1I
shows weak immunostaining for AM in the liver parenchyma of a
P-19 WT mouse, the hepatocytes, and in particular, the epithelial
cells of the bile duct in the liver of the TGF-β1 null mouse show
more intense staining for AM (Fig. 1J). Figure 1K shows that while
neurons in the brain of the WT mouse have a pattern of general
weak staining, many of the neurons in the brain of the TGF-β1 null
mouse have strong immunostaining (Fig. 1L). In the developing
postnatal heart, although some myocytes show some
immunostaining for AM, especially in the periphery of the heart of
the WT mouse (Fig. 1M), the intensity and distribution of AM
immunostaining is considerably stronger and more pronounced in
the cardiac myocytes of the TGF-β1 null mouse (Fig. 1N). Carti-
lage in the area of endochondral ossification as well as in forming
bone cells are more strongly immunostained for AM in the P-19
TGF-β1 null mouse (Fig. 1P) than in the WT littermate (Fig. 1 O).
We also performed immunohistochemical analysis for AM on
several organs from postnatal TGF-β1 null and WT mice over a
range of ages, including P-7, P-14, and P-19 mice (Table 1). The
intensity of immunohistochemical staining for AM was either
intense or moderate in all tissues examined of the P-7 WT mice
compared to weak staining in TGF-β1 null mice of the same age.
The intensity of staining for AM decreased to either moderate or
weak in all of the tissues examined in P-17 WT mice, while it
increased to moderate to strong levels in P-17 TGF-β1 null mice.
Table 1 also shows that immunostaining continued to decrease in
the heart and dorsal root ganglia and moderately in lung, liver,
kidney, chondrocytes, and brain of embryonic WT mice of both
ages compared to TGF-β1 null mice. A gradual elevation in AM
from younger to older postnatal TGF-β1 null mice would suggest
that this is a cumulative effect and may contribute to the lethality.
The coordinated change in AM suggests that it may play a key role
in the inflammatory response as well. AM appears to play a pivotal
role in both reprioritizing the biological needs of tissues and
organs during the various phases of inflammatory response as
well as a role in restoring homeostatic equilibrium to the organism.
Increased AM expression in the postnatal TGF-β1 null mouse
may mediate either pro-inflammatory activities or oppose these
actions. However, if AM opposes inflammatory activities in the
postnatal TGF-β1 mouse, it is unable to prevent inflammation and
death in this mouse.
To confirm the observations made by immunohistochemcal analy-
sis, namely that AM levels are higher in wildtype fetal mice than in
their TGF-β1 null littermates, total RNA was extracted from whole
embryos of different ages, cDNA was synthesized, and real time
polymerase chain reaction (PCR) amplification was performed with
primers for AM, and also for 18S rRNA as a house-keeping gene.
Fig. 2. Quantitative real time RT-PCR for adrenomedullin mRNA in
whole embryo extracts from TGF-β1 null and wildtype animals at E15
and E17 of intrauterine development. The statistical significance of the
differences observed between TGF-β1 null (KO) and wildtype (WT) animals
are expressed as a “p” value or as not significant (n.s.).
Fig. 3 (Left). Quantitative real time RT-PCR for adrenomedullin mRNA in tissue extracts from TGF-β1 null and wildtype animals at P14 of
postnatal development. The statistical significance of the differences observed between TGF-β1 null (KO) and wildtype (WT) animals are expressed
as a “p” value or as not significant (n.s.).
Fig. 4 (Right). Quantitative real time RT-PCR for adrenomedullin  mRNA in primary cultures of embryonic fibroblasts obtained from TGF-β1null
and wildtype mice. Wildtype fibroblasts were exposed to a neutralizing antibody against TGF-β1 (WT+Ab) or to saline (WT), and TGF-β1 null (KO)
fibroblasts were similarly exposed to saline before RNA extraction. The statistical significance of the differences observed between groups is expressed
as a “p” value.
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Figure 2 shows that the expression levels for AM mRNA, corrected
by house-keeping gene contents, were higher in the WT animals than
in their TGF-β1 null littermates at E15 and E17. At day 15, the
difference was not statistically significant, but at day 17, the p value
was 0.02.
Real time RT-PCR amplification was also used to evaluate the
expression of AM mRNA during postnatal development in the TGF-
β1 null mouse. Figure 3 shows the results obtained for P-14 mice. A
statistically significant decrease in AM mRNA expression was found
in the brain and liver of wildtype animals when compared to their TGF-
β1 null littermates. Differences of expression in other organs, such as
the kidney and the intestine, did not reach statistical significance, but
this is clearly understandable when we consider that for molecular
techniques, a complete homogenate of the tissue has to be prepared,
and in some cases a dilution effect may obscure the differences
observed by more cell-type specific in situ techniques such as
immunohistochemistry.
To complement our in vivo experiments, total RNA was also
extracted from primary cultures of mouse embryonic fibroblasts
(MEF) obtained from E18 TGF-β1 null and WT mice, cDNA was
synthesized, and real time PCR amplification was performed with
primers for AM as in vivo. Figure 4 shows a statistically significant
higher level of AM mRNA in cultured MEFs from wildtype mice
compared to TGF-β1 null mice and parallels our in vivo results. There
was also a decrease in the level of AM mRNA expression in MEFs
from wildtype mice after treatment with a neutralizing antibody to
TGF-β1 with a p value of 0.024, indicating that neutralization of TGF-
β1 induces downregulation of AM levels, in agreement with our
observations in TGF-β1 null animals. These studies indicate that
TGF-β1 regulates AM expression. One mechanism by which TGF-
β1 may regulate AM mRNA expression may be at the level of the AM
promoter. Analysis of the sequence of the mouse AM promoter
shows at least one potential Smad binding element by which TGF-
β1 signaling may be able to regulate AM mRNA expression, and this
will be needed to be addressed in future studies.
At this time, although we have demonstrated that an increase in
AM occurs in several tissues of the postnatal TGF-β1 null mouse, we
are unable to determine whether this increase is a cause or a
consequence of the pathology. It is also unclear whether increases
in AM in specific cells of affected tissues reflect an overflow from local
sites of production and action, or whether in some conditions,
increased AM has a hormonal function causing a decrease in
vascular resistance and a decrease in blood pressure, among other
effects. Our findings show an interaction between TGF-β1 and AM
and raise additional questions about their functions in the diseased
state.
Experimental Procedures
TGF-β1 null and WT mice were sacrificed using carbon dioxide
inhalation, embryos were removed from the uterus, and embryos and
postnatal tissues were placed immediately into formalin for paraffin
embedding and sectioning. Immunohistochemical staining for AM was
performed using the avidin-biotin complex technique with a previously
characterized polyclonal antibody to AM (Miller et al., 1996). In addition,
MEFs harboring the null or wildtype TGF-β1 allele were derived from E18
mice to establish TGF-β1 null and WT fibroblasts that were cultured over
multiple passages to obtain sufficient primary cells. The MEFs from
wildtype mice were treated for 24 h with 30 µg/ml neutralizing monoclonal
TGF-β1 antibodies from R&D Systems (Minneapolis, MN).
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